Search clinical trials for: intraperitoneal docetaxel

Total 2481 results

Nektar Therapeutics

Completed

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (ATTAIN)

Breast Cancer | Metastasis

United States, Australia, Belgium, Canada, France, Israel, Italy, Portugal, Spain, United Kingdom
Spanish Breast Cancer Research Group
Sanofi; Pfizer; Hoffmann-La Roche

Completed

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Breast Cancer

Spain
Karolinska University Hospital
German Breast Group; Austrian Breast & Colorectal Cancer Study Group; Swedish...

Unknown

Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients (PANTHER)

Breast Cancer

Sweden, Germany, Austria
National Cancer Institute (NCI)

Completed

Ketoconazole Plus Docetaxel to Treat Prostate Cancer

Prostatic Neoplasms

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
Sanofi
Cancer International Research Group (CIRG)

Completed

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Breast Neoplasms

United States, France, Brazil, Romania, Russian Federation, Australia, Spain, Sweden, Turkey, India, Slovakia, Taiwan, Belgium, Czech Republic, Tunisia, Uruguay, Argentina, Croatia, Austria, Egypt, Greece, Hungary, Ireland, Israel, Italy, Mexic... and more
University of Michigan Rogel Cancer Center

Terminated

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

Cancer of Larynx

United States
Centre Jean Perrin

Completed

Breast Cancer Treated by Neoadjuvant Chemotherapy

Individualized Chemotherapy

France
Pfizer

Completed

Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer

Prostatic Neoplasms

United States
Radboud University Medical Center
Sanofi; Amgen

Completed

Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer. (INTENS)

Breast Cancer

Netherlands
The First Affiliated Hospital with Nanjing Medical...
Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Not yet recruiting

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

Breast Cancer | HR+/HER2- Breast Cancer
AstraZeneca

Recruiting

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric Cancer | Gastroesophageal Junction Cancer

Canada, Spain, United Kingdom, China, France, Italy, Vietnam, Germany, United States, India, Japan, Taiwan, Thailand, Hong Kong, Switzerland, Poland
University of Chicago

Not yet recruiting

Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer (TARMAC)

Triple Negative Breast Cancer
Nationwide Children's Hospital
National Pediatric Cancer Foundation

Recruiting

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue (TINKS)

Pediatric Sarcoma, Refractory | Pediatric Sarcoma, Relapsed

United States
Janssen Pharmaceutical K.K.

Active, not recruiting

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Prostatic Neoplasms

Japan
Australasian Gastro-Intestinal Trials Group
Bristol-Myers Squibb; Bayer; Syneos Health; University of Sydney; National Cancer... and other collaborators

Active, not recruiting

RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb)

Gastro-Oesophageal Cancer

Korea, Republic of, Australia, Taiwan, United States, Germany, Japan, Spain, Italy, Austria
Jiangsu Simcere Pharmaceutical Co., Ltd.

Terminated

A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
The Christie NHS Foundation Trust
University of Leeds; National Institute for Health Research, United Kingdom; ...

Active, not recruiting

Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma (NET02)

Oncology | Neuroendocrine Carcinoma

United Kingdom
Dana-Farber Cancer Institute
Sanofi

Completed

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

Prostate Cancer

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
Eli Lilly and Company

Terminated

A Safety Study in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States
Emory University
Pfizer

Completed

Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers

Breast Cancer

United States
Ohio State University Comprehensive Cancer Center

Completed

Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer

Breast Cancer

United States
National Cancer Center Hospital East
Merck Sharp & Dohme LLC

Recruiting

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

Gastric Cancer

Japan
Second Affiliated Hospital, School of Medicine,...
Women's Hospital School Of Medicine Zhejiang University; Zhejiang Provincial... and other collaborators

Recruiting

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

HER2-negative Breast Cancer | Neoadjuvant Chemotherapy

China
Institut für Klinische Krebsforschung IKF GmbH...
Roche Pharma AG

Recruiting

Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (DANTE)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Germany, Switzerland
NSABP Foundation Inc
National Cancer Institute (NCI)

Active, not recruiting

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Breast Cancer

United States, Puerto Rico
Eli Lilly and Company

Terminated

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Puerto Rico
German Breast Group
Celgene; Amgen

Completed

Study of Nab-Paclitaxel in High Risk Early Breast Cancer (GAIN-2)

Breast Cancer

Germany
University of California, Irvine

Completed

Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
University of Turin, Italy

Unknown

The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial (EPIC)

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Stage IV, NSCLC

Italy
University of Kansas Medical Center

Completed

Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

Metastatic Prostate Cancer

United States
Western Regional Medical Center

Terminated

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Neohttp)

HER2-positive Breast Cancer | ER-positive Breast Cancer

United States
Hoffmann-La Roche

Completed

To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer

Breast Cancer

France
Bristol-Myers Squibb

Completed

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Advanced Cancer

United States, Canada
Peng Yuan

Unknown

Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
City of Hope Medical Center
California Institute for Regenerative Medicine (CIRM)

Active, not recruiting

A Blood Stem Cell Transplant for Sickle Cell Disease

Sickle Cell Disease | Anemia, Sickle Cell | Hemoglobinopathies | Thalassemia | Sickle Cell Disorder

United States
Hellenic Oncology Research Group

Terminated

Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer

Breast Cancer

Greece
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

Breast Cancer

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Squamous Cell Carcinoma of Head and Neck

United States, Australia, Canada, Denmark, France, Israel, Korea, Republic of, Norway, Portugal, Romania, Spain, Taiwan, United Kingdom, Colombia, Brazil
Astellas Pharma Global Development, Inc.

Recruiting

A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma (ILUSTRO)

Gastric Cancer | Pharmacokinetics of Zolbetuximab | Gastro-esophageal Junction (GEJ) Cancer | Pharmacokinetics of Oxaliplatin | Pharmacokinetics of Fluorouracil Bolus (5-FU)

United States, Japan, Italy, Korea, Republic of, Taiwan, France
AstraZeneca

Active, not recruiting

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)

Non-Small Cell Lung Cancer

France, Spain, United States, Canada, Korea, Republic of, Austria, Israel, Germany
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)

Non Small Cell Lung Cancer

United States, China, Hungary, Brazil, Argentina, Canada, France, Greece, Italy, Japan, Korea, Republic of, Romania, Spain, Taiwan, Turkey
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Terminated

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

Breast Cancer

United States
Hoffmann-La Roche

Completed

Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

Breast Cancer

India
Nasser Hanna, M.D.
Bristol-Myers Squibb; Hoosier Cancer Research Network

Terminated

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Suspended

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Breast Cancer

China
Fudan University

Completed

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

Breast Cancer
Zhejiang University
Zhejiang Cancer Hospital; First People's Hospital of Hangzhou; Second Affiliated... and other collaborators

Unknown

Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients (ESNDBCP)

Breast Cancer

China

Search clinical trials for: intraperitoneal docetaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations